Authors


Joshua I. Halpern

Latest:

Forecasting Returns When Patents Expire

Overestimating product reserves as loss of exclusivity (LoE) approaches can be a $75-million mistake


BY TARA HERINGTON, CARDINAL HEALTH SONEXUS™

Latest:

The outcomes-based reimbursement environment

A changing role for hubs in collecting critical data, raising adherence


Ed Schoonveld

Latest:

Policy and Population Health

Is the potential of a more formal policy integration for health issues and disease prevention a scary suggestion or a good Idea?


Vaishali Karnat, Cambridge Consultants

Latest:

The Pharma Industry's Place in a Connected Health World

New technologies are creating a powerful link between patients and healthcare providers. This Connected Health World has implications for pharmaceutical business practices



Thanos Kantarelis, Precision for Medicine

Latest:

Biosimilars: why deep discounts may become the dominant paradigm

European experience to date indicates a changing perspective on biosimilar pricing


Jody Fisher, SDI Health

Latest:

The Patient-Level Approach to Studying Healthcare

Longitudinal patient-level data answer pressing questions about patient safety, outcomes and medication acceptance


Michael Christel

Latest:

Community Pharmacies in Crisis: Navigating the Challenges and Closures

With today's pharmacy landscape shaken by unprecedented and wider disruption to healthcare support and delivery, community and independent entities strive to remain an integral cog in the mix.


Joe Tenhagen, Nosco Inc.

Latest:

On-Demand Digital Printing Rewires Pharma Packaging

Digital systems are changing the economics and functionality of scheduling and production of printed packaging


Alan Coukell, Pew Prescription Project

Latest:

After Heparin: Protecting Consumers from the Risks of Substandard and Counterfeit Drugs

Industry and FDA can—and must—do more to protect global pharmaceutical supply chains


Stephen Lagano, AltoMetrixs LLC

Latest:

Understanding Class of Trade Concepts

‘Class of Trade’ is a murky element of contracts and channel analytics that can have important legal implications


Angela Kerr, SpotSee

Latest:

Fortifying Vaccine Supply Chains

How they embrace collaboration will be key to the battle against RSV.


Glen Giovannetti

Latest:

Reshaping Biotechnology's Financing Relay Race

The current economic downturn may fuel the creation of new, more sustainable business models



Marina Aslanyan, Sparta Systems

Latest:

Make Adverse Events and Customer Complaints Part of a Holistic Quality Management System

Usually associated with manufacturing or laboratory processes, quality systems can improve post-marketing compliance efforts


Valentin Recker, Booz & Company

Latest:

Focusing pharma marketing on 'headroom'

In the race to improve product performance, not enough attention is paid to 'who's actually going to switch?'


Michael Johngren, Parallax Consulting

Latest:

A Process-Based Approach To Aggregate Spend

A Process-Based Assessment (PBA) is the first step to analyzing reporting needs


Philip Song, Becton Dickinson

Latest:

A growing preference for ready-to-administer vaccines: new guidelines, evidence, and trends

Vaccine administration is shifting from multidose vials to prefilled syringes for a host of important safety and economic considerations


Sheila W. Sawyer, Esq.

Latest:

Regulatory Focus on Off-Label Promotion Is Rising

While FDA guidance on appropriate medical communication has evolved, US Dept. of Justice attention the practice is intensifying


Jesse Mendelsohn, Model N

Latest:

Effective and proactive oversight of master data

Go-to safeguards for manufacturers in avoiding mismanagement of their business-central records


By Anthony Dellumo, Q Products & Services

Latest:

Big Pharma requires big help in protecting CRT products

An inside look at selection and implementation of passive thermal protection


Bob Sperber

Latest:

With coupons, pharma is saying 'Let's make a deal' to consumers

Pharma marketers become adept at refining coupon and voucher programs, while technology options multiply. Meanwhile payer criticism mounts


John Klimek, RPh, NCPDP

Latest:

NCPDP Standards for Accurate Billing, Reimbursement and Access

The National Council for Prescription Drug Programs’ (NCPDP) Billing Unit Standard (BUS) brings order to pharmaceutical transactions. Between it, the National Drug Code (NDC) and the Structured Product Label (SPL), all necessary commercial information about a product is known.


Kuyler Doyle, Campbell Alliance

Latest:

Preparing the Market for a New Drug with an Effective 'Medical Affairs Launch'

The Medical Affairs function can play a vital role in today’s product launch process


Josh Marsh, Cardinal Health Sonexus Access and Patient Support

Latest:

Shedding the Secondary Label

It's time to include hubs in the patient treatment journey



Gerry McDougall, PriceWaterhouseCoopers

Latest:

The Rise of 'Companion' Diagnostics for Specialty Pharmaceuticals

Under the theme of personalized medicine, in vitro diagnostics will play an increasingly important role in new drug entries and new therapies


BY Tanvi Kachhy, CareMetx

Latest:

Precision medicine and the importance of data

Patient-support Hub services are a vital repository of the patient journey


Jon Weisberg, SAFE-BioPharma Association

Latest:

Data security for Pharma

Cloud computing opens a new array of benefits--and challenges--to data-sharing


Nancy Dreyer, MPH, PhD, Quintiles Outcome

Latest:

Ensuring the quality of comparative effectiveness research

As payers seek higher-quality data from real-world treatment settings, the importance of reliable measures becomes critical

© 2024 MJH Life Sciences

All rights reserved.